Product
RSV MAT
2 clinical trials
1 indication
Indication
Respiratory Syncytial Virus InfectionsClinical trial
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated MothersStatus: Terminated, Estimated PCD: 2023-05-30
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of AgeStatus: Terminated, Estimated PCD: 2023-06-14